Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10221907 | 0.89 | MGAT2 (0.37) | HSD11B1MGAT2KDM1A | |
| SCHEMBL23606379 | 0.79 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL19223404 | 0.78 | MGAT2 (0.33) | HSD11B1MGAT2KDM1A | |
| SCHEMBL18133863 | 0.78 | MGAT2 (0.33) | HSD11B1MGAT2KDM1A | |
| SCHEMBL19223408 | 0.78 | MGAT2 (0.33) | HSD11B1MGAT2KDM1A | |
| SCHEMBL13819872 | 0.77 | MGAT2 (0.37) | HSD11B1MGAT2 | |
| SCHEMBL18199696 | 0.77 | CYP3A4 (0.40) | HSD11B1MGAT2 | |
| SCHEMBL4762461 | 0.73 | HSD11B1 (0.37) | HSD11B1MGAT2 | |
| SCHEMBL25025562 | 0.71 | KDM1A (0.33) | KDM1A | |
| SCHEMBL24567459 | 0.71 | KDM1A (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HSD11B1 3881/4885MGAT2 3066/4885KDM1A 3724/4885 |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | KRAS, NRAS, HRAS | HSD11B1 3881/4885MGAT2 3066/4885KDM1A 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.